Atlas market file · Equity · United States
Propanc Biopharma, Inc.PPCB
- Last close
- 1.36
- Change
- +15.25%
- 96-bar range
- 0.95 – 6.79
- As of
- 6 Aug 2026
Propanc Biopharma, Inc. is a pharmaceutical preparations issuer listed as PPCB on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
PPCB
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+6700.00% over the window).
Source rail: Yahoo Finance chart API (PPCB). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for PPCB. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
PPCB public profile
Pharmaceutical preparations issuer. Propanc Biopharma, Inc. is connected to current market context, cited company sources and its retained research file.
Propanc Biopharma, Inc. trades as PPCB on NASDAQ. Propanc Biopharma, Inc. (PPCB) has a latest verified close of 1.36, up 15.25%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files PPCB under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Propanc Biopharma, Inc. today
Propanc Biopharma (PPCB) reported a net loss of $6.4M and operating cash outflow of $4.1M in Q1 2026, per its 10-Q filing, despite touting advancements in its PRP cancer treatment pipeline. The company’s latest 8-K reveals the issuance of 3.2M new shares on July 14, 2026, exacerbating dilution concerns for existing shareholders.
Propanc’s core focus remains on developing PRP, a protease-based therapy targeting pancreatic, ovarian, and colorectal cancers. However, the product pipeline remains preclinical, with human trials not anticipated until 2027. Recent press releases highlight collaborations and assay development, but no revenue-generating products exist yet. The firm’s R&D spend of $169,660 in Q1 underscores the early-stage nature of its operations.
Financial strain is evident: the company’s $9.8M stockholders’ equity is dwindling, with liabilities at $3.5M. The $4,912 spent on property and equipment in Q1 suggests minimal infrastructure. Meanwhile, Propanc’s S-1 filing on July 17, 2026, indicates ongoing fundraising efforts, raising questions about sustainability without consistent cash infusions.
The stock’s recent volatility reflects market uncertainty over Propanc’s ability to transition from lab-based research to commercial viability. With no near-term catalysts beyond preliminary trial preparations, investors are left weighing scientific promise against harsh financial realities.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
PPCB technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on PPCB
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep PPCB research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
PPCB FAQ
What is Propanc Biopharma, Inc. (PPCB)?Propanc Biopharma, Inc. (PPCB) has a latest verified close of 1.36, up 15.25%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
Propanc Biopharma, Inc. (PPCB) has a latest verified close of 1.36, up 15.25%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for PPCB?Propanc Biopharma, Inc. (PPCB) has a latest verified close of 1.36, up 15.25%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
Propanc Biopharma, Inc. (PPCB) has a latest verified close of 1.36, up 15.25%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files PPCB under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the PPCB page updated?The PPCB public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The PPCB public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for PPCB?The PPCB file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:PPCB. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The PPCB file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:PPCB. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on PPCB?Yes. The workstation can open PPCB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open PPCB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this PPCB page investment advice?No. The PPCB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The PPCB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →